We explored the feasibility of using the APTW signal intensity as a surrogate biomarker to identify the methylation status of MGMT promoter in glioblastoma (GBM). Eighteen patients with newly diagnosed GBM were recruited and scanned. Results showed that the APTW signal intensities were significantly higher in the unmethylated MGMT promoter group than in the methylated MGMT promoter group. The area under the ROC curve (AUC) for APTW to differentiate these two GBM groups was 0.857. Preoperative APTW imaging may assist in predicting the MGMT promoter methylation status in patients with GBM.